For decades, the standard line on stopping psychiatric medications — particularly SSRIs, SNRIs, and benzodiazepines — was that “discontinuation symptoms” were mild, transient, and far less concerning than the underlying condition returning. Patients who reported severe and prolonged effects after tapering were often told they were experiencing relapse, not withdrawal. A growing body of research and patient testimony suggests that framing was substantially wrong, and the consequences of that error are still being absorbed.
The evidence has shifted significantly
A 2019 systematic review by Davies and Read, drawing on patient surveys and existing trials, found that more than half of antidepressant users experiencing discontinuation symptoms described them as severe, with nearly half reporting durations beyond several weeks. The UK’s Royal College of Psychiatrists updated its guidance in 2020 to acknowledge that withdrawal can be severe and prolonged for some patients, breaking from earlier assurances. Subsequent research has documented withdrawal phenomena including persistent sensory disturbances (“brain zaps”), sleep disruption, mood instability that didn’t precede medication, and akathisia — a profoundly distressing inner restlessness — in patients tapering even cautiously. Benzodiazepine withdrawal has been recognized as severe for longer, with protocols sometimes calling for tapers measured in years rather than weeks.
The misdiagnosis problem
Withdrawal symptoms can closely mimic the conditions the medications were prescribed for. A patient tapering an SSRI may experience anxiety, low mood, sleep difficulty, and irritability — the same cluster that originally led to the prescription. Clinicians, working from older guidance, often interpret these as relapse and reinstate the medication, sometimes at higher doses. The patient feels better when the drug returns, which seems to confirm the relapse interpretation but actually just confirms that withdrawal stopped. This dynamic has trapped people on medications for years longer than necessary, and has obscured the scale of withdrawal as a phenomenon by recoding it as ongoing illness.
Tapering protocols haven’t caught up
Standard taper schedules — halving doses every few weeks — were designed when withdrawal was assumed to be a brief inconvenience. They don’t reflect the receptor-occupancy dynamics that have since become clearer. Hyperbolic tapering, where dose reductions get smaller and slower as the dose itself shrinks, appears to be far better tolerated, but it requires tools many patients can’t access easily: liquid formulations, compounding pharmacies, or careful pill-cutting over months and sometimes years. Some clinicians have begun adopting these approaches; many haven’t. Patients researching their own tapers have built peer support communities online to fill the gap, an awkward situation that reflects how far formal guidance lags real-world need.
The bottom line
None of this argues against psychiatric medication, which remains essential for many people and clearly improves quality of life when used appropriately. The argument is narrower: withdrawal from these medications can be a serious medical event, the historical reassurances that minimized it were not well-founded, and patients who suspect they’re experiencing it deserve to be heard rather than dismissed as relapsing. If you are considering stopping any psychiatric medication, work closely with a knowledgeable clinician on a slow, individualized taper. Professional support during this process is genuinely valuable, and going it alone is rarely the right call.
Leave a Reply